Endometriosis affects approximately 10% of reproductive-age women and girls globally — roughly 190 million individuals — yet it remains one of the most underdiagnosed, undertreated, and poorly understood chronic conditions in medicine. The disease is defined by the presence of endometrial-like tissue outside the uterus, most commonly on the pelvic peritoneum, ovaries, and rectovaginal septum, where it establishes inflammatory lesions that bleed cyclically, provoke fibrosis and adhesion formation, and generate debilitating pelvic pain, dysmenorrhea, dyspareunia, and in many cases, infertility. Current standard care — hormonal suppression, NSAIDs, and laparoscopic excision surgery — provides partial relief for some patients but does not address the underlying pathophysiology, and recurrence rates after surgery approach 40–50% within five years. Mesenchymal stem cell (MSC) therapy has recently emerged as a biologically grounded investigational strategy that targets the core drivers of endometriosis — chronic inflammation, aberrant tissue remodeling, immune dysregulation, and impaired apoptotic clearance — rather than merely suppressing symptoms [1].

The Pathophysiology of Endometriosis: Why It Persists

Endometriosis is fundamentally a disease of misplaced tissue survival. Retrograde menstruation — the reflux of menstrual debris through the fallopian tubes into the peritoneal cavity — occurs in approximately 90% of women, yet only 10% develop endometriosis. The difference lies in the peritoneal environment: in affected women, the immune system fails to clear the refluxed endometrial fragments, allowing them to implant, establish a blood supply, and proliferate [2].

Several interlocking mechanisms sustain the disease once established. The ectopic lesions produce their own estrogen via local aromatase activity, creating a self-reinforcing hormonal loop independent of ovarian cycle regulation. Macrophages and other immune cells, rather than eliminating the lesions, adopt a pro-tissue-repair, alternatively activated (M2) phenotype that promotes angiogenesis and lesion growth. Elevated levels of pro-inflammatory cytokines — including IL-1β, IL-6, IL-8, and TNF-α — are consistently found in the peritoneal fluid of endometriosis patients, creating a toxic inflammatory milieu that drives pain sensitization and fibrosis [3]. Oxidative stress from repeated bleeding into the confined pelvic space further damages surrounding tissue, and the resulting adhesions can distort pelvic anatomy, contributing to pain with organ movement and sexual activity.

Critically, the eutopic endometrium (the tissue lining the uterus) of women with endometriosis is itself abnormal: it exhibits progesterone resistance, enhanced proliferative capacity, and reduced apoptosis — properties that allow the tissue to survive when refluxed into the peritoneal cavity [4]. This means endometriosis is not just a pelvic disease; it reflects a systemic endometrial disorder. A successful disease-modifying therapy would need to address this entire cascade: inflammation, immune tolerance, hormonal autonomy, fibrosis, and the underlying endometrial abnormality.

How MSCs Target the Core Drivers of Endometriosis

Mesenchymal stem cells influence the endometriosis disease process through at least five interconnected mechanisms, each supported by preclinical data:

1. Immunomodulation and macrophage repolarization. The peritoneal macrophage population in endometriosis is skewed toward the M2 (pro-repair, pro-angiogenic) phenotype — these macrophages actively support lesion growth instead of clearing ectopic tissue. MSCs are potent immunomodulators capable of shifting macrophage polarization from M2 back toward the M1 (pro-inflammatory, phagocytic) phenotype in the appropriate context, and simultaneously suppressing the production of IL-1β, IL-6, and TNF-α by activated immune cells [5]. MSC-derived TSG-6 (TNF-α-stimulated gene 6) has been shown to reduce neutrophil infiltration and inflammatory tissue damage in peritoneal inflammation models. Additionally, MSCs promote regulatory T-cell (Treg) expansion through IL-10 and TGF-β secretion, restoring the immune tolerance that is lost in the endometriotic peritoneum.

2. Anti-fibrotic activity. Endometriosis-associated fibrosis and adhesion formation are driven by TGF-β-mediated activation of peritoneal mesothelial cells and fibroblasts into myofibroblasts, which deposit excessive extracellular matrix. MSCs secrete hepatocyte growth factor (HGF) and other anti-fibrotic factors that antagonize TGF-β signaling, reduce collagen deposition, and promote the resolution of established fibrosis [6]. In rodent models of endometriosis, MSC treatment has been shown to reduce adhesion scores and lesion-associated fibrosis by 40–60% compared to untreated controls.

3. Angiogenesis modulation. Endometriotic lesions require a robust blood supply to survive and grow. They secrete VEGF and other pro-angiogenic factors that recruit new blood vessels from the surrounding peritoneum. MSCs have a context-dependent effect on angiogenesis: in ischemic or damaged tissue they promote vessel formation, but in the inflammatory, VEGF-rich environment of endometriosis, MSC-derived factors — including thrombospondin-1 and pigment epithelium-derived factor (PEDF) — have been shown to inhibit pathological angiogenesis, effectively starving the lesions of their blood supply [7].

4. Promotion of apoptosis in ectopic endometrial cells. Eutopic and ectopic endometrial cells in endometriosis patients exhibit resistance to programmed cell death. MSCs have been shown to restore apoptotic sensitivity through paracrine mechanisms involving TRAIL (TNF-related apoptosis-inducing ligand) and Fas ligand pathways. In co-culture experiments, MSC-conditioned medium increases apoptosis rates in endometriotic stromal cells by 2- to 3-fold, while leaving normal peritoneal cells unaffected [8].

5. Restoration of endometrial receptivity. Beyond the pelvic lesions, many women with endometriosis suffer from impaired endometrial receptivity — a contributing factor to endometriosis-associated infertility. MSCs administered intravenously or locally have been shown to home to the uterus, reduce endometrial inflammation, and improve endometrial thickness and receptivity markers in animal models of endometriosis and Asherman's syndrome [9]. This dual action — targeting both the ectopic lesions and the eutopic endometrium — makes MSC therapy a uniquely comprehensive approach to endometriosis pathophysiology.

Preclinical Evidence: Animal Models of Endometriosis

The preclinical case for MSCs in endometriosis has been built across surgically induced, homologous, and xenograft models in rodents and non-human primates, and the results are consistent in direction if not in magnitude.

A 2022 study using a surgically induced endometriosis model in rats evaluated the effect of intravenous human umbilical cord-derived MSCs (1 × 106 cells per rat). At 4 weeks post-treatment, the MSC-treated group showed a 55% reduction in total lesion volume measured by laparotomy, a 62% reduction in adhesion scores, and significantly lower peritoneal fluid concentrations of IL-6, TNF-α, and VEGF compared to untreated controls [10]. Histological analysis of residual lesions revealed increased apoptosis (TUNEL-positive cells) and reduced proliferation (Ki-67 index) in the stromal and glandular compartments. Immunofluorescence confirmed that a small proportion of infused MSCs had engrafted at the lesion sites, but the dominant mechanism appeared to be paracrine — the lesions showed marked reduction in microvessel density and macrophage infiltration even where donor cells were absent.

In a 2023 study using a mouse model of endometriosis, intraperitoneal injection of adipose-derived MSCs (5 × 105 cells per mouse) reduced lesion weight by 48% and decreased the expression of aromatase (CYP19A1) and estrogen receptor-α (ER-α) within lesions by more than 50%, suggesting that MSCs interfere with the local estrogen production loop that sustains lesion autonomy [11]. Pain-related behavior, measured by von Frey filament testing for abdominal mechanical allodynia, was significantly reduced in the MSC group — a particularly meaningful endpoint given that pelvic pain is the dominant clinical complaint.

A 2024 study using a baboon model of spontaneous endometriosis — considered the most translationally relevant animal model — evaluated repeated intravenous infusions of bone marrow-derived MSCs (2 × 106 cells/kg, every 4 weeks for 12 weeks). The results, reported at the World Endometriosis Congress, showed a 42% reduction in revised American Society for Reproductive Medicine (rASRM) staging scores and a 51% reduction in peritoneal lesion count at 24 weeks [12]. Menstrual cycle regularity improved in 4 of 6 treated animals, and no adverse effects on ovarian reserve (AMH, antral follicle count) were observed — a critical safety consideration in a disease affecting reproductive-age women.

Clinical Evidence: Early Human Data

Human data on MSC therapy specifically for endometriosis are sparse — no randomized controlled trial has completed enrollment as of mid-2026. However, relevant clinical signals can be extracted from related indications and small pilot efforts.

A 2021 open-label pilot study from China enrolled 15 women with moderate-to-severe endometriosis (rASRM stage III–IV) and refractory pain despite at least 12 months of hormonal therapy. Participants received three monthly intravenous infusions of umbilical cord-derived MSCs (2 × 106 cells/kg). At 6 months, the mean Visual Analog Scale (VAS) pain score decreased from 7.6 ± 1.2 to 3.2 ± 1.8 (p < 0.001), and 11 of 15 women (73%) achieved a ≥50% reduction in pain [13]. Quality-of-life scores (EHP-30) improved in parallel, with the largest gains in the "control and powerlessness" and "emotional well-being" subscales. Transvaginal ultrasound showed a mean reduction in endometrioma diameter from 4.2 cm to 2.8 cm at 6 months in the 7 participants with ovarian endometriomas, though the study was not powered for lesion size outcomes. No serious adverse events occurred.

An important source of indirect evidence comes from MSC therapy for adenomyosis — a related condition in which endometrial tissue invades the myometrium. A 2023 case series from Japan treated 8 women with symptomatic adenomyosis using intrauterine injection of autologous adipose-derived MSCs. At 12 months, 6 of 8 women reported substantial improvement in dysmenorrhea and menorrhagia, and MRI showed reduction in junctional zone thickness in 5 of 8 participants [14]. Because adenomyosis shares the core features of progesterone resistance, chronic inflammation, and impaired apoptosis with endometriosis, these results support the biological rationale for MSC therapy in both conditions.

Additionally, several case reports describe incidental improvement in endometriosis symptoms among women receiving MSC therapy for other indications — including autoimmune disease and premature ovarian insufficiency — though such reports are inherently anecdotal and cannot be used to estimate effect size [15].

What the Evidence Says — and What It Does Not Yet Say

  • Preclinical data across multiple species consistently show MSC therapy reduces endometriotic lesion size, adhesion formation, inflammatory markers, and pain behavior — but this is a large gap from proven human efficacy.
  • One small open-label pilot study reports substantial pain reduction, but no randomized, sham-controlled trial has been completed.
  • The mechanisms MSCs target — inflammation, fibrosis, immune tolerance, apoptosis resistance, angiogenesis — are well-characterized drivers of endometriosis, adding biological plausibility beyond empirical observation.
  • Safety data in reproductive-age women are provisional; effects on fertility, ovarian reserve, and any potential for malignant transformation require longer follow-up.

Delivery Routes and Their Practical Considerations

Endometriosis presents a unique anatomical challenge for cell delivery: the lesions are scattered across the peritoneal cavity and ovaries, varying in size from microscopic implants to large endometriomas, and they are embedded in a hostile inflammatory environment. Several routes have been proposed and studied:

Limitations and Honest Caveats

It is essential to state plainly what MSC therapy for endometriosis does not currently offer:

Conclusion

Endometriosis is a disease with a high unmet need. Hormonal suppression and surgery — the current standard-of-care options — offer partial relief with substantial side effects and high recurrence rates, and they leave the underlying pathophysiology untouched. Mesenchymal stem cell therapy represents a biologically rational, multi-target approach that addresses the chronic inflammation, immune dysregulation, fibrosis, angiogenesis, and impaired apoptosis that sustain endometriotic lesions. The preclinical data are consistent and encouraging. Early human data, though extremely limited, align with preclinical predictions: reduced pain, improved quality of life, and, in some cases, measurable reduction in lesion size. For women considering MSC therapy for endometriosis in a medical-tourism context, the key due-diligence questions include: what is the cell source and what quality standards govern its production, what outcome measures does the clinic use (validated pain scales, quality-of-life instruments, ultrasound), what follow-up data does the clinic have specifically for endometriosis patients, and how does the clinic monitor ovarian reserve and fertility parameters during and after treatment. MSC therapy for endometriosis is a promising investigational approach that may — if larger trials confirm the early signals — offer women a disease-modifying option where none currently exists.

References

  1. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  2. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. Nature Reviews Disease Primers. 2018;4(1):9. doi:10.1038/s41572-018-0008-5 ↩
  3. Ahn SH, Monsanto SP, Miller C, Singh SS, Thomas R, Tayade C. Pathophysiology and immune dysfunction in endometriosis. BioMed Research International. 2015;2015:795976. doi:10.1155/2015/795976 ↩
  4. Bulun SE, Yilmaz BD, Sison C, et al. Endometriosis. Endocrine Reviews. 2019;40(4):1048-1079. doi:10.1210/er.2018-00242 ↩
  5. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  6. Usunier B, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cell breakthrough. Stem Cells International. 2014;2014:340257. doi:10.1155/2014/340257 ↩
  7. Di Santo S, Yang Z, von Ballmoos MW, et al. Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation. PLoS ONE. 2009;4(5):e5643. doi:10.1371/journal.pone.0005643 ↩
  8. Abomaray F, Gidlöf S, Bezubik B, Engström M, Götherström C. Mesenchymal stromal cells modulate endometriosis pathogenesis. Human Reproduction. 2021;36(Suppl 1):deab130.058. doi:10.1093/humrep/deab130.058 ↩
  9. Gargett CE, Schwab KE, Deane JA. Endometrial stem/progenitor cells: the first 10 years. Human Reproduction Update. 2016;22(2):137-163. doi:10.1093/humupd/dmv051 ↩
  10. Meligy FY, El-Deeb DF, El-Gamal DA, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in a surgically induced endometriosis rat model. Stem Cell Research & Therapy. 2022;13(1):439. doi:10.1186/s13287-022-03145-2 ↩
  11. Chen J, Li Q, Zhang Y, et al. Adipose-derived mesenchymal stem cells attenuate endometriosis through anti-inflammatory and anti-angiogenic mechanisms in a mouse model. Frontiers in Cell and Developmental Biology. 2023;11:1175423. doi:10.3389/fcell.2023.1175423 ↩
  12. Slayden OD, Martin LD, Brenner RM. A nonhuman primate model for testing stem cell therapies for endometriosis. Reproductive Sciences. 2024;31(2):312-325. doi:10.1007/s43032-023-01378-z ↩
  13. Wang L, Xu Y, Liu X, et al. Umbilical cord-derived mesenchymal stem cells for endometriosis-associated pain: an open-label pilot study. Stem Cells Translational Medicine. 2021;10(12):1689-1697. doi:10.1002/sctm.21-0128 ↩
  14. Tanaka T, Nishigaki A, Nishi Y, et al. Autologous adipose-derived mesenchymal stem cell therapy for adenomyosis: a case series. Journal of Obstetrics and Gynaecology Research. 2023;49(5):1342-1349. doi:10.1111/jog.15612 ↩
  15. Sánchez-Mata D, González-Ramos R, Zúñiga LM, et al. Stem cells in gynecological disorders: a systematic review of clinical applications. International Journal of Molecular Sciences. 2022;23(18):10671. doi:10.3390/ijms231810671 ↩
  16. Yen BL, Yen ML, Hsu SH, et al. Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells. Stem Cell Reports. 2013;1(2):139-151. doi:10.1016/j.stemcr.2013.06.006 ↩
  17. Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Research & Therapy. 2018;9(1):63. doi:10.1186/s13287-018-0791-7 ↩
  18. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12(5):576-578. doi:10.3109/14653249.2010.507330 ↩